Hyphens Pharma International Ltd. · SGX:1J5
Hyphens Pharma International — FY2021 Earnings Presentation
23 slides from Hyphens Pharma International's earnings presentation, Mar 2, 2022
Slide 1: General Announcement: Results Briefing FY2021
GENERAL ANNOUNCEMENT::RESULTS BRIEFING FY2021 Issuer & Securities Issuer/ Manager HYPHENS PHARMA INTERNATIONAL LIMITED Securities HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5 Stapled Security No Announcement Details Announcement Title General Announcement Date &Time of Broadcast 02-Mar-2022 12:1
Slide 2: Hyphens Pharma International Limited Results Briefing FY2021
HYPHENS PHARMA INTERNATIONAL LIMITED Results Briefing FY2021 2 MARCH 2022
Slide 3: Disclaimer
DISCLAIMER This presentation has been prepared by Hyphens Pharma International Limited (the "Company" and, together with its subsidiaries, the "Group"). This content in this presentation is being furnished to you on a confidential basis and solely for your information and neither this presentation n
Slide 4: Financial Results
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 5: 1.1 Financial Performance
1.1 FINANCIAL PERFORMANCE Revenue (S$’m) Profit After Tax (S$’m) 125.9 6.8 115.9 116.2 121.0 6.5 6.2 6.1 107.4 5.4 2017# 2018# 2019# 2020# 2021 2017 2018* 2019 2020** 2021 # Restated for prior years to be consistent with FY2021 * Incl IPO exp; ** Incl JSS & Covid-related stock prov
Slide 6: 1.2 Income Statement
Notes 1.2 INCOME STATEMENT • Revenue increased across all business segments and most geographical locations. S$’000 FY2021 FY2020 Variance Revenue 125,883 120,977 4% • Improved GPM to 38.2% in FY2021 from 36.1% in FY2020. Gross profit 48,083 43,636 10% Other income & gains 964 2,295 -58% • Decline i
Slide 7: 1.3 Revenue by Business Segments
1.3 REVENUE BY BUSINESS SEGMENTS 140.0 120.0 100.0 Revenue S$’mil 53% 51% 52% 80.0 60.0 13% 15% 15% 40.0 20.0 34% 34% 33% 0.0 FY2019 FY2020 FY2021 Specialty 62.0 62.0 65.6 Proprietary 14.5 18.1 19.1 Hypermart 39.7 40.9 41.2 Total (restated) 116.2 121.0 125.9
Slide 8: 1.4 Revenue by Geographical Segments
1.4 REVENUE BY GEOGRAPHICAL SEGMENTS FY2019 FY2020 FY2021 7.2 , 6% 8.4 , 7% 9.6 , 8% 8.0 , 7% 7.9 , 7% 10.6 , 8% 57.5 , 60.8 , 64.1 , 50% 50% 51% 43.5 , 43.9 , 41.6 , 37% 36% 33% Singapore Vietnam Malaysia Others Note: Revenue in S$’mil & restated prior years to be consistent with FY2021
Slide 9: 1.5 EBITDA Margin by Business Segments
1.5 EBITDA MARGIN BY BUSINESS SEGMENTS 12.4% 12.4% 9.9% 9.7% 9.5% 8.5% * 7.0% Notes: 3.6% 2.8% Due to restatement of revenue in prior years to be consistent with FY2021, prior years’ EBITDA margins have been updated accordingly. Specialty pharma principals Proprietary brands Medical hypermart & digi
Slide 10: Financial Position
2 FINANCIAL POSITION S$’000 31 Dec 2021 31 Dec 2020 Total assets 98,412 81,458 Inventories 25,076 16,888 Trade & other receivables 28,543 23,736 Cash & cash equivalents 19,461 27,526 Total liabilities 43,779 34,283 Trade & other payable 33,563 27,555 Bank borrowings 6,075 2,396 Total equity 54,633 4
Slide 11: Cashflow Statement
3 CASHFLOW STATEMENT S$'000 FY2021 FY2020 Cashflow from operating activities Profit before tax 8,256 7,108 Adjustments for non-cash/non-op items 2,661 1,893 Changes in working capital (3,464) (3,810) Tax paid (1,415) (1,061) Cashflow from operating activities 6,038 4,130 Cashflow used in investing a
Slide 12: Proposed Dividend
4 PROPOSED DIVIDEND S$’000 Dividend Yield* Div / Net Profit FY2021 0.67 cents 2.3% 30.2% (subj to shareholders’ approval) FY2020 0.62 cents 2.1% 30.2% FY2019 1 cent 3.4% 46.0% FY2018 0.55 cents 1.9% 30.5% * Yield is computed based on total dividends declared for the financial year divided by closing
Slide 13: Business Updates
uu e _J > Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 14: Patent pending in other countries / regions
Patent pending in 11 other countries / regions
Slide 15: Ceradan
Ceradan’ + eps Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 16: Ocean Health and Unity brands
Ocxsaz Lae MULTIVITAMIN & MINERALS OMEGA-3 FISH OIL 1000MG Unity TRUSTED BRAND OMEGA-3 popurak | SUPPLEMENT AWARDS Singapore's Leading Specialty P i Hyphens
Slide 17: Best-selling fish oil (Omega-3) supplement
*Best-selling fish oil (Omega-3) supplement in major retail pharmacies from 2013 to 2021. ^In comparison with our large Omega-3 Fish Oil bottle pack.
Slide 18: Wellaway: First HSA-registered e-pharmacy in Singapore
THE STRAITS TIMES o ea.) ™ we WELLAWAY U First HSA-registered e-pharmacy in Singapore launched Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 19: Leading Healthcare-Focused Distributor
LEADING HEALTHCARE-FOCUSED DISTRIBUTOR Pharmaceutical Products Nutraceutical Products Medical Devices
Slide 20: More than 20 Years of Track Record
> 20 YEARS OF TRACK RECORD MORE THAN MORE THAN MORE THAN 150 1,000 40 PRODUCTS CUSTOMERS BRAND PRINCIPALS H O S P I T AL S • P O L Y C L I N I C S S P E C I AL I S T S • G P s
Slide 21: Business Outlook
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 22: Investing for Growth
INVESTING FOR GROWTH 1. Investment in Proprietary Brands 2. Internationalisation 3. Going Digital 4. Strengthen Specialty Pharma Portfolio 5. Acquisitions Challenges : COVID-19
Slide 23: Hyphens Pharma International Limited (SGX: 1J5)
Hyphens Pharma International Limited (SGX: 1J5) 16 Tai Seng Street, Level 4, Singapore 534138 www.hyphensgroup.com
Hyphens Pharma International — FY2021 Earnings Presentation on 6ix